PMA device
i-FACTOR® Peptide Enhanced Bone Graft
Cerapedics, LLC · Filler, Bone Void, Synthetic Peptide (NOX, Class III) · First FDA decision Nov 3, 2015, newest Sep 13, 2024
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
6
PMA pathway
Device trials
21
Naming "i-FACTOR"
MAUDE reports
50
Brand "i-FACTOR", since 2015
PubMed studies
241
Mentioning "i-FACTOR"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing i-FACTOR® Peptide Enhanced Bone Graft
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 6 decisions filed under this name.
- i-FACTOR® Peptide Enhanced Bone GraftPMA supplement
P140019-S011 · Decided Sep 13, 2024 · 91 days after receipt · Normal 180 Day Track
Device type: Filler, bone void, synthetic peptide (NOX) · Orthopedic Surgery
- i-FACTOR Peptide Enhanced Bone GraftPMA supplement
P140019-S004 · Decided Jul 22, 2020 · 37 days after receipt · Normal 180 Day Track No User Fee
Device type: Filler, bone void, synthetic peptide (NOX) · Orthopedic Surgery
- i-FACTOR Peptide Enhanced Bone GraftPMA supplement
P140019-S003 · Decided Oct 11, 2019 · 177 days after receipt · Normal 180 Day Track No User Fee
Device type: Filler, bone void, synthetic peptide (NOX) · Orthopedic Surgery
3 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "i-FACTOR", any status and sponsor, newest update first.
Amina Fouad FaragAcademic, hospital or other
NCT07932912 · 66 participants · Start Nov 1, 2023 · Primary completion Nov 30, 2024
Device: 0.8% High-Molecular-Weight Hyaluronic Acid Gel · For: Periodontitis
Sites: Giza, Egypt
Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaAcademic, hospital or other
NCT06714097 · 20 participants (planned) · Start Jan 2027 · Primary completion Oct 2027
Device: AI · For: Stroke; Moyamoya Disease; Cerebral Amyloid Angiopathy
Sites: Milan, Italy
University of MichiganAcademic, hospital or other
NCT07840521 · 90 participants (planned) · Start Nov 30, 2026 · Primary completion Mar 2032
Device: Low-intensity focused ultrasound pulsation (LIFUP); Functional Magnetic Resonance Imaging (fMRI) and 2 more · For: Consciousness, Level Altered
Sites: Ann Arbor, Michigan
18 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "i-FACTOR", and for the whole product code for context.
This brand
50 reports: 1 malfunction, 49 injury, 0 death
Whole product code NOX
178 reports: 7 malfunction, 171 injury, 0 death
Newest reports for this brand
- I-FACTORInjury
3007155473-2026-26342 · Received May 14, 2026 · Event dated Apr 14, 2026
Device type: Filler, Bone Void, Synthetic Peptide (NOX)
Device problem as coded: Insufficient Device Problem Information
Patient problem as coded: Wound Dehiscence; Insufficient Information
- I-FACTORInjury
3007155473-2026-26340 · Received Apr 24, 2026 · Event dated Apr 4, 2022
Device type: Filler, Bone Void, Synthetic Peptide (NOX)
Device problem as coded: Appropriate Device Problem Term/Code Not Available
Patient problem as coded: Wound Dehiscence; Local Reaction; Seroma; Post Operative Wound Infection; Swelling/ Edema
- I-FACTORInjury
3007155473-2026-26339 · Received Apr 24, 2026 · Event dated Apr 22, 2024
Device type: Filler, Bone Void, Synthetic Peptide (NOX)
Device problem as coded: Appropriate Device Problem Term/Code Not Available
Patient problem as coded: Neck Pain; Neck Stiffness; Insufficient Information; Limb Pain
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-1056-2022 · Started Apr 14, 2022
Reason given: Patient chart label contains incorrect Part Number and volume amount.
Cause as FDA categorized it: Under Investigation by firm · Device type: Filler, Bone Void, Synthetic Peptide (NOX)
Published research
The most relevant PubMed records for "i-FACTOR"[tiab]. The summary above synthesizes these.
- Inherited complement deficiencies.
Lachmann PJ · Philos Trans R Soc Lond B Biol Sci · 1984Review
- Longitudinal research on bipolar disorders.
Salvatore P, Tohen M, Khalsa HM, et al. · Epidemiol Psichiatr Soc · 2007Editorial, Research Support, N.I.H., Extramural
- Controversies in Spine Surgery: Is i-Factor Superior to Bone Morphogenic Protein for Achieving Spine Fusion?
Bernatz JT, Fisher MWA, Pinter ZW, et al. · Clin Spine Surg · 2023
- ESCRT Requirements for Murine Leukemia Virus Release.
Bartusch C, Prange R · Viruses · 2016Research Support, Non-U.S. Gov't
- Hijacking host components for bacterial biofilm formation: An advanced mechanism.
Mirzaei R, Ranjbar R · Int Immunopharmacol · 2022Review
- Complement-mediated thrombotic microangiopathy associated with lupus nephritis.
Park MH, Caselman N, Ulmer S, et al. · Blood Adv · 2018Clinical Trial, Multicenter Study
- Identifying Soccer Teams' Styles of Play: A Scoping and Critical Review.
Plakias S, Moustakidis S, Kokkotis C, et al. · J Funct Morphol Kinesiol · 2023Scoping Review
- Indirect Self-Destructiveness and Emotional Intelligence.
Tsirigotis K · Psychiatr Q · 2016
- [H Factor Deficiency: A Case with an Atypical Presentation].
Rocha AP, Borges M, Neves C, et al. · Acta Med Port · 2019Case Reports
- Altuvoct: Innovative Medicinal Products Benefit from Innovative Approaches to Regulatory Assessment.
Kerwash E, Malamatari M, Johnston JD · Life (Basel) · 2025
- Emotional Intelligence of Women Who Experience Domestic Violence.
Tsirigotis K, uczak J · Psychiatr Q · 2016
- Maternal Inherited Thrombophilia in Monochorionic Twin Pregnancy with Twin-Twin Transfusion Syndrome.
Giannubilo SR, Fiorelli A, Marzioni D, et al. · J Clin Med · 2022
Other devices of this type
Also filed under product code NOX.
- Augment® Bone GraftBiomimetic Therapeutics, LLC · PMA 2022
- AUGMENT InjectableBiomimetic Therapeutics, LLC · PMA 2019
- PearlMatrix P-15 Peptide Enhanced Bone Graft (PearlMatrix Bone Graft)Cerapedics, Inc. · PMA 2025
- PearlMatrix Bone GraftCerapedics, Inc. · PMA 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.